Semaglutide Shows Promise in Patients with Obesity-Related Heart Failure

Heart failure with preserved ejection fraction (HFpEF) poses an increasing clinical challenge with few effective treatments available.

The aim of a new review was to examine the potential of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, as a treatment option for HFpEF.

Preliminary studies suggest that semaglutide may offer benefits such as symptom relief, weight loss, and possibly improved exercise capacity. However, the impact of semaglutide on exercise capacity and heart function is not yet fully established, and its anti-inflammatory effects need further investigation. The safety profile of semaglutide appears generally favorable, with gastrointestinal side effects being the most frequently reported adverse events.

Additional research is needed, including studies with longer follow-up periods, direct comparisons with current treatments, and exploration of optimal dosing and mechanisms of action, to better define semaglutide's role in HFpEF management. While semaglutide shows promise in improving symptoms, aiding weight loss, and potentially affecting the underlying mechanisms of HFpEF, further studies are essential to confirm its efficacy and fully unlock its potential for treating this condition.

Source: Olatunji G, Aderinto N, Kokori E, et al. Current Problems in Cardiology. 2024 Jun 11:102697.